Meeting
2014 Gastrointestinal Cancers Symposium
A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.
Authors
Su Pin Choo
National Cancer Centre Singapore, Singapore, Singapore
Su Pin Choo , Clarinda Wei Ling Chua , Yasuhide Yamada , Sun Young Rha , Wei Peng Yong , Chee Kian Tham , Matthew Ng , Wai Meng David Tai , Hwee Yong Lim , Iain B. Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01736410
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 127)
DOI
10.1200/jco.2014.32.3_suppl.127
Abstract #
127
Poster Bd #
D33
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.
First Author: Yelena Y. Janjigian
Poster
2018 ASCO Annual Meeting
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, single-arm study.
First Author: Feng Wang
Poster
2017 ASCO Annual Meeting
KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.
First Author: Yung-Jue Bang
Poster
2016 ASCO Annual Meeting
Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.
First Author: Charles S. Fuchs